3.
Baseline characteristics of included studies
| Author | Year | Treatment record | No. of
cases |
No. < 65 years | No. of
female |
No. of
ECOG = 0–1 |
No. of
never smoker |
No. of
adenocarcinoma |
Outcome assessment |
| NA: not available; OS: overall survival; PFS: progression-free survival; ORR, overall response rate; DCR, disease control rate. | |||||||||
| Lin et al. | 2015 | Yes | 56 | 40 | 35 | 39 | 38 | 56 | OS, PFS |
| Tang et al. | 2015 | Yes | 170 | 85 | 77 | NA | 113 | 145 | OS, PFS |
| Meniawy et al. | 2016 | Yes | 33 | 12 | 17 | 32 | NA | 23 | OS, PFS |
| Sorensen et al. | 2016 | Yes | 38 | 13 | 23 | 31 | 9 | NA | OS, PFS |
| Cho et al. | 2017 | Yes | 319 | NA | 194 | 318 | 114 | 319 | OS, PFS |
| Kobayashi et al. | 2018 | Yes | 32 | 13 | 20 | NA | 27 | NA | OS, PFS |